Welcome to our dedicated page for EXELIXIS SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
EXELIXIS, INC. executive Dana Aftab, EVP of Research and Development, reported two tax-related share dispositions. On February 15, 2026, a total of 26,485 and 12,720 shares of common stock were withheld at $43.92 per share to cover taxes due upon vesting of performance-based restricted stock units granted on March 4, 2022 and restricted stock units granted on January 5, 2023. These are tax-withholding dispositions, not open-market sales. After these transactions, Aftab directly holds 693,897 shares of common stock, which include 414,043 shares underlying restricted stock units and performance stock units granted on March 31, 2025. In addition, there are 5,835 shares held indirectly through the Exelixis 401(k) Plan as of February 13, 2026.
Exelixis, Inc. director Bob Oliver reported mixed activity in company stock. On February 13, 2026, he sold 9,088 shares of common stock in an open-market transaction at $43.61 per share and separately sold 21,162 shares at a weighted average price of $43.90 per share, with individual trades between $43.90 and $43.96 as noted in a footnote.
On the same date, he exercised an option for 9,088 shares of common stock, recorded as both a derivative exercise and an acquisition of common shares at an exercise price of $19.28 per share. A footnote states this option originally covered 36,353 shares and became fully exercisable on May 31, 2023. Another footnote notes 18,900 restricted stock units that will convert into common shares upon vesting.
EXELIXIS, INC. senior vice president and general counsel Brenda Hefti reported insider transactions in company common stock. She sold 18,669 shares in an open-market sale at an average price of $44.01 per share under a pre-arranged Rule 10b5-1 trading plan. Separately, 5,430 shares were withheld by the company to cover taxes due on the vesting of performance-based restricted stock units. After these transactions, she continued to hold a substantial direct equity position, along with additional restricted stock units, performance stock units expected to deliver 95,956 shares upon vesting, and 5,527 shares held indirectly through the company’s 401(k) plan.
Insider sale notice: A reporting person submitted a Form 144 indicating a proposed sale of 64,117 shares on 02/18/2026. The filing also reports prior sales of 42,422 shares on 02/17/2026 for $1,880,439.99.
EXEL reports a Form 144 notice proposing sales of common stock. The notice names Morgan Stanley Smith Barney LLC as the broker-dealer and includes numeric entries such as 821,663.76 and 259,708,689 alongside an 02/18/2026 date. The filing also lists two performance share lines dated 01/16/2025 and 02/15/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the planned sale of 99,574 Common shares with an aggregate value of $4,382,506.87 on 02/18/2026. The notice lists prior issuances and exercises of Common stock on several dates, including 03/29/2021, 04/01/2019, 05/21/2021, 05/23/2020, and 04/04/2022.
A shareholder of Exelixis filed a notice to sell 42,422 shares of common stock under Rule 144. The shares are expected to be sold on or about 02/17/2026 through NASDAQ, with Morgan Stanley Smith Barney LLC listed as the broker.
These shares were acquired on 02/17/2026 through a stock option exercise from the issuer, paid for in cash, and have an indicated aggregate market value of $1,880,439.99. The filing notes that total shares outstanding are 259,708,689 for context.
A company insider has filed a Form 144 indicating an intent to sell 30,617 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,337,035.20. The shares, classified as performance shares, were acquired from the issuer on 02/15/2026, with the same date listed for payment. The approximate sale date is 02/17/2026 on the NASDAQ market. Over the prior three months, Christopher J. Senner sold 34,278 common shares for $1,473,964.28. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about the issuer.
Exelixis insider Patrick Joseph Haley has filed a notice to sell up to 67,814 shares of the company’s common stock under Rule 144. The planned sale, through Morgan Stanley Smith Barney, has an indicated aggregate market value of $2,951,082.94 based on the figures in the notice.
The shares to be sold were acquired as performance shares from the issuer on January 15, 2026 (37,421 shares) and February 15, 2026 (30,393 shares), with payment listed as not applicable. The notice also shows that Haley previously sold common shares during November 2025 in three transactions totaling tens of thousands of shares, with individual gross proceeds of $1,194,070.94, $421,052.00, and $1,431,757.23.
Exelixis Inc. has a shareholder planning to sell restricted shares under Rule 144. The notice covers 3,856 shares of Exelixis common stock to be sold through UBS Financial Services on NASDAQ, with an approximate aggregate market value of $165,383.84. These shares were acquired as restricted stock units from the issuer on 01/05/2026, the same date listed as the payment date. The filing also reports that Exelixis had 259,708,689 shares of common stock outstanding, providing context for the size of this planned sale.